Work

Weekly MLN9708, an investigational oral proteasome inhibitor (PI), in relapsed/refractory multiple myeloma (MM): Results from a phase I study after full enrollment.

Year: 2013

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2013.31.15_suppl.8514

Authors: Shaji Kumar, William Bensinger, Todd M. Zimmerman, Craig B. Reeder, James R. Berenson, Deborah Berg, Ai-Min Hui, Neeraj Gupta, Alessandra Di Bacco, Jiang Yu, Yaping Shou, Ruben Niesvizky

Institutions: Mayo Clinic, Fred Hutch Cancer Center, University of Chicago, Mayo Clinic in Arizona, Institute for Myeloma & Bone Cancer Research, Takeda Oncology (United States), NewYork–Presbyterian Hospital, Cornell University

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2597497113

Cites:

Cited by: 16

Related to: 10